-
Product Insights
NewPre-Eclampsia – Drugs In Development, 2024
Empower your strategies with our Pre-Eclampsia – Drugs In Development, 2024 report and make more profitable business decisions. Hypertension during pregnancy is termed pre-eclampsia. It generally occurs during the second trimester or after giving birth. Although there is no exact cause but stress, abnormal placentation is believed to lead to pre-eclampsia. Obesity, underlying diseased conditions hypertension, diabetes, kidney disease, or genetic causes may also lead to this. When pathologically examined high levels of protein in the urine (proteinuria), renal insufficiency, and...
-
Product Insights
NewRetinopathy Of Prematurity – Drugs In Development, 2024
Empower your strategies with our Retinopathy Of Prematurity – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder, which usually develops in both eyes, is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. Risk factors for the development of ROP include prematurity, extremely low birth weight, and multiple...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewRetinopathy – Drugs In Development, 2024
Empower your strategies with our Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of a systemic disease such as diabetes or hypertension. The Retinopathy...
-
Product Insights
Mengo Project
The Mengo Project is a potash project in Congo. It is currently under construction. Empower your strategies with our Mengo Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital information...
-
Product Insights
Dengta City Biomass Cogeneration Project
Dengta City Biomass Cogeneration Project is a biopower project located in Liaoning, China. The project is owned and being developed by Guangdong Evergreen Group Co Ltd. The project is at the permitting stage. Empower your strategies with our Dengta City Biomass Cogeneration Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....